Avalo Therapeutics, Inc. (NASDAQ:AVTX) Stock Has Consensus Price Target of $45.10

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have been given an average recommendation of “Moderate Buy” by the fourteen analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $37.00.

Several analysts have recently weighed in on the company. Guggenheim restated a “neutral” rating on shares of Avalo Therapeutics in a report on Friday, October 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Avalo Therapeutics in a report on Wednesday, September 16th. Wedbush dropped their price target on shares of Avalo Therapeutics from $34.00 to $22.00 and set an “outperform” rating on the stock in a research report on Friday, October 23rd. Weiss Ratings raised shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Oppenheimer set a $16.00 price target on shares of Avalo Therapeutics in a report on Monday.

Avalo Therapeutics Price Performance

AVTX opened at $6.75 on Wednesday. The company has a market capitalization of $362.00 million, a price-to-earnings ratio of -1.54 and a beta of 0.68. Avalo Therapeutics has a 1-year low of $6.53 and a 1-year high of $24.27. The business has a 50 day moving average price of $15.54 and a two-hundred day moving average price of $16.21.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). Equities analysts expect that Avalo Therapeutics will post -2.95 EPS for the current fiscal year.

Insider Activity

In related news, CFO Christopher Sullivan sold 12,394 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total value of $202,394.02. Following the sale, the chief financial officer directly owned 39,900 shares in the company, valued at $651,567. The trade was a 23.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 23,258 shares of company stock valued at $395,434. Insiders own 4.46% of the company’s stock.

Institutional Trading of Avalo Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP lifted its position in shares of Avalo Therapeutics by 34.3% during the 2nd quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company’s stock valued at $14,244,000 after acquiring an additional 196,882 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Avalo Therapeutics during the 2nd quarter worth $1,945,000. Renaissance Technologies LLC grew its holdings in shares of Avalo Therapeutics by 556.4% in the 1st quarter. Renaissance Technologies LLC now owns 120,114 shares of the company’s stock worth $1,793,000 after acquiring an additional 101,814 shares during the last quarter. DV Trading LLC acquired a new position in shares of Avalo Therapeutics in the 1st quarter worth $5,376,000. Finally, Sei Investments Co. acquired a new position in shares of Avalo Therapeutics in the 1st quarter worth $849,000. 87.06% of the stock is owned by institutional investors and hedge funds.

About Avalo Therapeutics

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are intended to address conditions with significant unmet medical needs.

Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.